MANNKIND CORP (MNKD) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US56400P7069
MANNKIND CORP financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 348.97 m USD |
| Gross profit | 322.17 m USD |
| Operating income | 38.80 m USD |
| EBIT | 7.18 m USD |
| Net income | 5.86 m USD |
| Diluted EPS – continuing operations | 0.02 USD |
Full history since 2000, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About MANNKIND CORP
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
More stocks
- Oil-Dri Corp of America (ODC)
- KCTech Co Ltd (281820.KS)
- Uniphar PLC (UPR.IR)
- Chengdu Haoneng Tech Co Ltd (603809.SS)
- Shanghai Aladdin Biochemical Technology Co. Ltd. A (688179.SS)
- Lamda Development SA (LAMDA.AT)
- SkyeChip Berhad (5357.KL)
- Genertec Universal Medical Group Co Ltd (2666.HK)
- SYoung Group Co Ltd (300740.SZ)
- Guangzhou Lingwe Technology Co. Ltd. A (301373.SZ)
- Saratoga Investama Sedaya (SRTG.JK)
- TENNANT CO (TNC)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.